Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2

NARecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

June 30, 2026

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Indole-3-propionic acid (IPA)

Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Active capsules are taken orally and contain 250 mg of IPA each.

DIETARY_SUPPLEMENT

Placebo

Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Placebo capsules are taken orally and contain maltodextrin.

Trial Locations (1)

2600

RECRUITING

Optic Neuritis Clinic, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup Municipality

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

University of Southampton

OTHER

lead

Glostrup University Hospital, Copenhagen

OTHER

NCT07105514 - Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2 | Biotech Hunter | Biotech Hunter